Article
GT Drug Product Formulation — The CMC Sections That Determine Active Vector Delivery
The drug product section of a GT CMC package is where physics, chemistry, and virology converge. An AAV or lentiviral vector that survives manufacturing can still fail at…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
GT Drug Product Formulation — The CMC Sections That Determine Active Vector Delivery
The drug product section of a GT CMC package is where physics, chemistry, and virology converge. An AAV or lentiviral vector that survives manufacturing can still fail at…
Article
ICH Q13 Continuous Manufacturing — Regulatory Science Framework and Submission Strategy
ICH Q13 became a finalized international guideline in 2022 and was implemented by FDA and EMA in short succession — making it the first ICH guideline that fully…
Article
Empty and Full AAV Capsids — Analytics and Specification at the Center of Every Review
No single analytical question in AAV CMC generates more CBER comments than the full/empty capsid ratio. And yet most early-stage packages treat it as a secondary characterization attribute.
Article
ICH Q14 Analytical Procedure Development — The Updated Standard Every CMC Team Must Implement
ICH Q14 and the updated ICH Q2(R2) represent the most significant change to pharmaceutical analytical regulatory science since Q2(R1) was issued in 1994. They introduce a lifecycle approach…
Article
Adventitious Agent Testing — What the CBER Viral Safety Package Must Contain
The viral safety package for a gene therapy vector is not analogous to a standard biologics viral clearance study. CBER evaluates it differently — and the gaps are…
Article
Real-Time Release Testing — Regulatory Framework and the CMC Evidence Required for FDA Approval
Real-time release testing is the regulatory mechanism by which a drug product manufacturer replaces end-product testing with real-time process measurements. FDA has approved RTRT programs across multiple drug…
Article
Raw Materials in Gene Therapy — The Upstream Control Gap That Follows You to BLA
In gene therapy manufacturing, impurity profiles are largely determined before fermentation begins. The raw material and starting material strategy you define at IND becomes the compliance liability you…
Article
ICH New CMC Guideline Intelligence
ICH Q2(R2) and its companion ICH Q14 were finalized in November 2023 as a paired guideline set that fundamentally reframes analytical method validation — not as a one-time…
Article
Gene Therapy Potency — CBER’s Exacting Expectations for Lot Release Testing
A potency assay for a gene therapy product is not just a release test. It is the primary evidence that your manufacturing process consistently produces a biologically active…
Article
Continuous Manufacturing — FDA Quality by Design Expectations and the CMC Submission Package
Continuous manufacturing has crossed from demonstration project to regulatory expectation. The FDA has approved more than a dozen drug products manufactured by continuous processes, issued ICH Q13 as…
Article
AAV Vector Characterization — The CQA Framework for CBER Analytical Review
An AAV drug substance section is not complete because it has a titer and a purity profile. It is complete when it demonstrates understanding of the full CQA…
Article
XGene CMC Digital Transformation Roadmap — The 18-Month Implementation Plan
Most pharmaceutical companies have a CMC digital transformation vision — and most of them have had the same vision for three years, with minimal implementation, because they are…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.